Weekly Paclitaxel-carboplatin Plus Bevacizumab as First Line Therapy for Patients With Triple Negative (ER-,PR-,HER2-) Metastatic Breast Cancer. A Multicenter Phase I-II Study
Breast cancer with absent or low expression of hormone receptors and HER2 (triple negative)
does not respond to hormonal or biological therapy with trastuzumab. However, triple
negative breast cancers are highly sensitive to chemotherapy. The combination of paclitaxel
and carboplatin administered on a weekly basis is active and well tolerated. Recently,
initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab demonstrated
prolonged progression-free survival, as compared with paclitaxel alone
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall Response Rate
Objective responses confirmed by CT or MRI (on 3rd and 6th cycle)
No
Dimitris Mavrudis, MD
Principal Investigator
University Hospital of Crete
Greece: National Organization of Medicines
CT/08.02
NCT00691379
April 2008
June 2013
Name | Location |
---|